IDEAYA Biosciences, Inc.
IDYA
Xếp hạng trong cổ phiếu
#4509
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to... IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Giá cổ phiếu
$35.54
Vốn hóa thị trường
$3.43B
Thay đổi (1 ngày)
5.12%
Thay đổi (1 năm)
16.49%
Quốc gia
US
Giao dịch IDEAYA Biosciences, Inc. (IDYA)
Danh mục
Healthcare
Tỷ lệ P/B của IDEAYA Biosciences, Inc. (IDYA)
Tỷ lệ P/B vào October 2026 TTM: 2.60
Theo các báo cáo tài chính và giá cổ phiếu mới nhất của IDEAYA Biosciences, Inc., tỷ lệ P/B hiện tại (TTM) là 2.60. Vào cuối năm 2023, công ty có P/B là 3.30.
Lịch sử tỷ lệ P/B của IDEAYA Biosciences, Inc. từ 2017 đến 2026
Tỷ lệ P/B vào cuối mỗi năm
| Năm | Tỷ lệ P/B | Thay đổi |
|---|---|---|
| 2026 (TTM) | 2.60 | 31.31% |
| 2024 | 1.98 | -39.85% |
| 2023 | 3.30 | 52.91% |
| 2022 | 2.15 | -22.03% |
| 2021 | 2.76 | 58.34% |
| 2020 | 1.75 | 15.49% |
| 2019 | 1.51 | -146.43% |
| 2018 | -3.26 | -67.85% |
| 2017 | -10.12 | 0.00% |
Tỷ lệ P/B của các công ty tương tự hoặc đối thủ cạnh tranh
| Công ty | Tỷ lệ P/B | Chênh lệch Tỷ lệ P/B | Quốc gia |
|---|---|---|---|
| 6.251 | 140.42% |
US
|
|
| 13.2547 | 409.80% |
US
|
|
| 4.208 | 61.85% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 137.78% |
NL
|
